European Community Advisory Board meeting on HIV with Gilead Sciences (September 2022)

Back to the "Events" list
  • 9 - 10 September 2022
  • Frankfurt

A European Community Advisory Board (ECAB) meeting between members from EATG and Gilead Sciences will be held in Frankfurt am Main on September 09th, 2022, to discuss topics of interest to the community, such as questions related to safety and implementation of new HIV treatments

 

The ECAB meeting will be followed by a training session on September 10th, 2022 with Nadine Jaschinski (PhD student and study coordinator at the International Cohort Consortium of Infectious Disease – RESPOND) on RESPOND and cardiovascular disease and risk factors in PLHIV.

 

The European Community Advisory Board (ECAB) is a platform that brings together civil society, scientific researchers, the pharmaceutical industry and other stakeholders to address key science and access issues related to HIV and its main co-infections. It is a network of individual community experts and people living with HIV who represent the diverse needs, interests, and concerns of the European HIV community. ECAB members meet regularly with key stakeholders to ensure the HIV community is represented and listened to in the research and development process.

Practical Information

  • European Community Advisory Board meeting on HIV with Gilead Sciences (September 2022): Date: 09 – 10 September 2022 / full day
    Venue: Hotel NH Frankfurt Airport, Mörfelder Str. 113, 65451, Frankfurt am Main, Germany.
    Registration link: No registration link – only for members in the ECAB pool who applied

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.